Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.62 |
| ▸ | MMP2 | P08253 | 7/20 | 0.33 |
| ▸ | MMP1 | P03956 | 6/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.33 |
| ▸ | STAT6 | P42226 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16176459 | 1.00 | TUBB1 (0.62) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL20723955 | 1.00 | TUBB1 (0.62) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL19282571 | 1.00 | TUBB1 (0.62) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL16176461 | 1.00 | TUBB1 (0.62) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL21086693 | 0.95 | TUBB1 (0.56) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL16176311 | 0.92 | TUBB1 (0.58) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL19282582 | 0.92 | TUBB1 (0.58) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL16176313 | 0.92 | TUBB1 (0.58) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL16176309 | 0.92 | TUBB1 (0.58) | TUBB1MMP2MMP1MMP3MMP9 | |
| SCHEMBL16183185 | 0.92 | TUBB1 (0.60) | TUBB1MMP2MMP1MMP3ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | claimed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | claimed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | claimed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| EP-2968440-B1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-06-05 | — | — | EP | disclosed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| US-9522876-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. | 2016-12-20 | — | — | US | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | TUBB1 216/4885MMP2 537/4885MMP1 2565/4885 |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885MMP2 2853/4885MMP1 3227/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | TUBB1 236/4885MMP2 2411/4885MMP1 2550/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | TUBB1 216/4885MMP2 537/4885MMP1 2565/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | TUBB1 216/4885MMP2 537/4885MMP1 2565/4885 |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885MMP2 2853/4885MMP1 3227/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885MMP2 2853/4885MMP1 3227/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | TUBB1 106/4885MMP2 2853/4885MMP1 3227/4885 |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, CCNB2 | TUBB1 107/4885MMP2 2858/4885MMP1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.